Researcher Profile

Researcher Profile

Raymond Hohl, MD, PhD

Raymond Hohl, MD, PhD

University Professor in Oncology, Department of Medicine
Division of Hematology and Oncology
Professor, Department of Pharmacology
Scientific Program:Next-Generation Therapies
Disease Teams:
Bone Marrow Transplantation
Leukemia and Lymphoma
rjh35@psu.edu
View Website

Research Interests

  • Neoplasms
  • Terpenes
  • Therapeutics
  • Lovastatin
  • Proteins
  • Prenylation
  • Cell Line
  • Diphosphonates
  • Leukemia
  • farnesyl pyrophosphate
  • geranylgeranyl pyrophosphate
  • Pharmacokinetics

Clinical Trials

Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation
Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
Clofarabine Pre-conditioning followed by Hematopoietic Stem Cell Transplant with Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) In Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
A Phase II, Multicenter, Randomized, Open-Label Trial of GEN1046 as monotherapy and in Combination with Anti-cancer Therapy in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer who failed first-line Standard of Care therapy with an Immune Checkpoint Inhibitor
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Recent Publications

2022

Manfredi, B, Neighbors, JD & Hohl, RJ 2022, 'Cytotoxic Effects of the Schweinfurthin Analog 5'-Methylschweinfurthin G in Malignant Plasma Cells', Pharmacology, vol. 107, no. 9-10, pp. 510-523. https://doi.org/10.1159/000525299
Cioccio, J, Rakszawski, K, Zheng, H, Nickolich, M, Naik, S, Wirk, B, Rybka, W, Ehmann, C, Silar, B, Vajdic, C, Shah, N, Tuanquin, L, Greiner, R, Brown, V, Hohl, R, Claxton, D, Mineishi, S, Minagawa, K & Shike, H 2022, 'Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis', Annals of Hematology. https://doi.org/10.1007/s00277-022-05077-2
Shah, N, Cioccio, J, Rakszawski, K, Zheng, H, Nickolich, M, Naik, S, Wirk, B, Rybka, W, Ehmann, C, Silar, B, Vajdic, C, Mierski, J, Zhou, S, Shike, H, Greiner, R, Brown, V, Hohl, R, Claxton, D, Mineishi, S, Minagawa, K & Tuanquin, L 2022, 'Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide', Leukemia Research, vol. 123, 106969. https://doi.org/10.1016/j.leukres.2022.106969
Zhao, C, Bartock, M, Jia, B, Shah, N, Claxton, DF, Wirk, B, Rakszawski, KL, Nickolich, MS, Naik, SG, Rybka, WB, Ehmann, WCC, Hohl, RJ, Valentin, J, Bernas-Peterson, M, Gerber, EM, Zimmerman, M, Mierski, JA, Mineishi, S & Zheng, H 2022, 'Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant', Journal of Hematology and Oncology, vol. 15, no. 1, 64. https://doi.org/10.1186/s13045-022-01287-3
Weissenrieder, JS, Weissenkampen, JD, Reed, JL, Green, MV, Zheng, C, Neighbors, JD, Liu, DJ & Hohl, RJ 2022, 'RNAseq reveals extensive metabolic disruptions in the sensitive SF-295 cell line treated with schweinfurthins', Scientific reports, vol. 12, no. 1, 359. https://doi.org/10.1038/s41598-021-04117-7
Zhang, R, Neighbors, JD, Schell, TD & Hohl, RJ 2022, 'Schweinfurthin induces ICD without ER stress and caspase activation', OncoImmunology, vol. 11, no. 1, 2104551. https://doi.org/10.1080/2162402X.2022.2104551
Koubek, EJ, Weissenrieder, JS, Ortiz, LE, Nwogu, N, Pham, AM, Weissenkampen, JD, Reed, JL, Neighbors, JD, Hohl, RJ & Kwun, HJ 2022, 'Therapeutic Potential of 5′-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma', Viruses, vol. 14, no. 9, 1848. https://doi.org/10.3390/v14091848

2021

Weissenrieder, JS, Reed, JL, Moldovan, GL, Johnson, MT, Trebak, M, Neighbors, JD, Mailman, RB & Hohl, RJ 2021, 'Antipsychotic drugs elicit cytotoxicity in glioblastoma multiforme in a calcium-dependent, non-D2 receptor-dependent, manner', Pharmacology Research and Perspectives, vol. 9, no. 3, e00689. https://doi.org/10.1002/prp2.689

2020

Zheng, H, Mineishi, S, Claxton, D, Zhu, J, Zhao, C, Jia, B, Ehmann, WC, Rybka, WB, Naik, S, Songdej, N, Drabick, JJ & Hohl, RJ 2021, 'A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia', American Journal of Hematology, vol. 96, no. 2, pp. E46-E50. https://doi.org/10.1002/ajh.26043
Bluethmann, SM, Wang, M, Wasserman, E, Chen, C, Zaorsky, NG, Hohl, RJ & McDonald, AC 2020, 'Prostate cancer in Pennsylvania: The role of older age at diagnosis, aggressiveness, and environmental risk factors on treatment and mortality using data from the Pennsylvania Cancer Registry', Cancer medicine, vol. 9, no. 10, pp. 3623-3633. https://doi.org/10.1002/cam4.3003
McDonald, AC, Wasserman, E, Lengerich, EJ, Raman, JD, Geyer, NR, Hohl, RJ & Wang, M 2020, 'Prostate cancer incidence and aggressiveness in appalachia versus non-appalachia populations in Pennsylvania by urban-rural regions, 2004–2014', Cancer Epidemiology Biomarkers and Prevention, vol. 29, no. 7, pp. 1365-1373. https://doi.org/10.1158/1055-9965.EPI-19-1232
Wang, M, Wasserman, E, Geyer, N, Carroll, RM, Zhao, S, Zhang, L, Hohl, R, Lengerich, EJ & McDonald, AC 2020, 'Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014', BMC Cancer, vol. 20, no. 1, 394. https://doi.org/10.1186/s12885-020-06902-5

2019

Huang, X, Sterling, NW, Du, G, Sun, D, Stetter, C, Kong, L, Zhu, Y, Neighbors, J, Lewis, MM, Chen, H, Hohl, RJ & Mailman, RB 2019, 'Brain cholesterol metabolism and Parkinson's disease', Movement Disorders, vol. 34, no. 3, pp. 386-395. https://doi.org/10.1002/mds.27609
Weissenrieder, JS, Neighbors, JD, Mailman, RB & Hohl, RJ 2019, 'Cancer and the dopamine D2 receptor: A pharmacological perspective', Journal of Pharmacology and Experimental Therapeutics, vol. 370, no. 1, pp. 111-126. https://doi.org/10.1124/jpet.119.256818
Jia, B, Zhao, C, Rakszawski, KL, Claxton, DF, Christopher Ehmann, W, Rybka, WB, Mineishi, S, Wang, M, Shike, H, Bayerl, MG, Sivik, JM, Schell, TD, Drabick, JJ, Hohl, RJ & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107
Allen, BG, Bodeker, KL, Smith, MC, Monga, V, Sandhu, S, Hohl, R, Carlisle, T, Brown, H, Hollenbeck, N, Vollstedt, S, Greenlee, JD, Howard, MA, Mapuskar, KA, Seyedin, SN, Caster, JM, Jones, KA, Cullen, JJ, Berg, D, Wagner, BA, Buettner, GR, TenNapel, MJ, Smith, BJ, Spitz, DR & Buatti, JM 2019, 'First-in-human phase I clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma', Clinical Cancer Research, vol. 25, no. 22, pp. 6590-6597. https://doi.org/10.1158/1078-0432.CCR-19-0594
Larson-Casey, JL, Vaid, M, Gu, L, He, C, Cai, GQ, Ding, Q, Davis, D, Berryhill, TF, Wilson, LS, Barnes, S, Neighbors, JD, Hohl, RJ, Zimmerman, KA, Yoder, BK, Longhini, ALF, Hanumanthu, VS, Surolia, R, Antony, VB & Brent Carter, A 2019, 'Increased flux through the mevalonate pathway mediates fibrotic repair without injury', Journal of Clinical Investigation, vol. 129, no. 11, pp. 4962-4978. https://doi.org/10.1172/JCI127959
Zhao, C, Jia, B, Wang, M, Schell, TD, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Songdej, N, Sivik, JM, Hohl, RJ, Zeng, H & Zheng, H 2020, 'Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML', British Journal of Haematology, vol. 188, no. 5, pp. 674-684. https://doi.org/10.1111/bjh.16228
Weissenrieder, JS, Reed, JL, Green, MV, Moldovan, GL, Koubek, EJ, Neighbors, JD & Hohl, RJ 2020, 'The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells', Pharmacology, vol. 105, no. 1-2, pp. 19-27. https://doi.org/10.1159/000502562

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)